1. Home
  2. GSL vs TRVI Comparison

GSL vs TRVI Comparison

Compare GSL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSL

Global Ship Lease Inc New

HOLD

Current Price

$41.00

Market Cap

1.4B

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$14.29

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSL
TRVI
Founded
2007
2011
Country
Greece
United States
Employees
7
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GSL
TRVI
Price
$41.00
$14.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
11
Target Price
$44.00
$21.55
AVG Volume (30 Days)
254.7K
1.8M
Earning Date
05-18-2026
05-05-2026
Dividend Yield
6.34%
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.95
$5.38
52 Week High
$42.70
$16.12

Technical Indicators

Market Signals
Indicator
GSL
TRVI
Relative Strength Index (RSI) 55.18 51.15
Support Level $36.97 $10.07
Resistance Level $41.40 $16.12
Average True Range (ATR) 0.97 0.80
MACD 0.03 -0.05
Stochastic Oscillator 53.33 40.11

Price Performance

Historical Comparison
GSL
TRVI

About GSL Global Ship Lease Inc New

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: